Aldara Related Published Studies
Well-designed clinical trials related to Aldara (Imiquimod)
Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts. [2008.07]
Treatment of vulvar intraepithelial neoplasia with topical imiquimod. [2008.04.03]
Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. [2008.04]
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. [2008.04]
A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. [2008]
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. [2007.12.06]
Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. [2007.11]
Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. [2007.11]
A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. [2007.10]
Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. [2007.08]
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. [2007]
Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. [2006.12]
An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. [2006.07]
Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. [2006.06]
Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. [2006.01]
Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. [2006.01]
Double-blind, randomized, placebo-controlled, prospective study evaluating the tolerability and effectiveness of imiquimod applied to postsurgical excisions on scar cosmesis. [2005.11]
Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. [2005.09.15]
Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. [2005.08]
Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. [2005.06]
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. [2005.05]
Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. [2005.04]
5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. [2004.12]
[Effects of imiquimod on latent human papillomavirus anal infection in HIV-infected patients] [2004.11]
Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. [2004.10]
Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. [2004.09]
Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. [2004.08]
Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. [2004.08]
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. [2004.05]
Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. [2004.05]
Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. [2003.11]
Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. [2003.02]
Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. [2002.12]
A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. [2002.11]
Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. [2002.10]
Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study. [2002.10]
Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation. [2002.09.02]
Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. [2002.09]
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. [2002.09]
Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. [2001.05]
Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. [2001.04]
Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. [2001.01]
Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. [2000.10]
Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study. [2000.09]
Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. [2000.07]
A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. [1999.12.03]
Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. [1999.12]
Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. [1999.08]
A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. [1998.08]
Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts. [1998.07.01]
Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study. [1998.07]
Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. [1998.05]
Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. [1998.04]
Treatment of genital warts with an immune-response modifier (imiquimod). [1998.02]
Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. [1998.01]
Other research related to Aldara (Imiquimod)
Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. [2008.10.18]
Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A. [2008.09]
Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. [2008.08.15]
Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis. [2008.08]
Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. [2008.08]
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. [2008.07.01]
[Localization and size as prognostic factors of response to treatment with 5% imiquimod cream in non circumcised males with penile condyloma acuminata] [2008.07]
Involution of infantile haemangiomas after imiquimod 5% cream. [2008.07]
Pyogenic granuloma: complete remission under occlusive imiquimod 5% cream. [2008.07]
Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna. [2008.05]
Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head. [2008.05]
Bowen's disease of the penis treated with topical imiquimod 5% cream. [2008.05]
Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy. [2008.05]
Vasodilatory adverse events associated with topical imiquimod 5 percent cream. [2008.04.15]
Complete resolution of Paget disease of the vulva with imiquimod cream. [2008.04]
Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. [2008.04]
Optimal Frequency of Imiquimod (Aldara) 5% Cream for the Treatment of External Genital Warts in Immunocompetent Adults: A Meta-Analysis. [2008.03.20]
Imiquimod for restoring local immunity in a renal transplant patient with persistent keratoacanthoma. [2008.03.15]
Imiquimod in mycosis fungoides. [2008.03]
Treatment of lentigo maligna with imiquimod before staged excision. [2008.02]
Advances in the use of topical imiquimod to treat dermatologic disorders. [2008.02]
Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. [2008.01]
A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. [2008.01]
Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas. [2008.01]
Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children. [2008.01]
Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. [2008.01]
Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. [2008]
Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin? [2007.12]
Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod. [2007.12]
Earlier eradication of intra-anal warts with argon plasma coagulator combined with imiquimod cream compared with argon plasma coagulator alone: a prospective, randomized trial. [2007.12]
Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies. [2007.12]
A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. [2007.12]
Update on actinic keratosis in clinical trial experience with imiquimod. [2007.12]
Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. [2007.12]
Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. [2007.12]
Imiquimod treatment of papilloma virus and DMBA /TPA-induced cutaneous skin cancer in Mastomys coucha: an unique animal model system useful for preclinical studies. [2007.12]
Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis. [2007.11.05]
Pyogenic granuloma in children: treatment with topical imiquimod. [2007.11]
Epidermodysplasia verruciformis: unsuccessful therapeutic approach with imiquimod. [2007.11]
Earlier Eradication of Intra-Anal Warts with Argon Plasma Coagulator Combined with Imiquimod Cream Compared with Argon Plasma Coagulator Alone: A Prospective, Randomized Trial. [2007.10.04]
A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. [2007.10.03]
Treatment of lentigo maligna with imiquimod 5% cream. [2007.10]
Laser-assisted tattoo removal with topical 5% imiquimod cream. [2007.09]
Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. [2007.09]
Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. [2007.09]
Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. [2007.09]
|
